These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17224711)

  • 1. Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002.
    Reist C; Mintz J; Albers LJ; Jamal MM; Szabo S; Ozdemir V
    J Clin Psychopharmacol; 2007 Feb; 27(1):46-51. PubMed ID: 17224711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment.
    Cohen D; Dekker JJ; Peen J; Gispen-de Wied CC
    Eur Neuropsychopharmacol; 2006 Apr; 16(3):187-94. PubMed ID: 16263247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic medications: metabolic and cardiovascular risk.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 4():8-13. PubMed ID: 17539694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scientific standards: critical comments on the pharmacoepidemiological study of second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia.
    Cohen D
    J Clin Psychopharmacol; 2008 Aug; 28(4):461-2; author reply 462-4. PubMed ID: 18626279
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.
    Gau SS; Chung CH; Gau CS
    J Clin Psychopharmacol; 2008 Jun; 28(3):271-8. PubMed ID: 18480683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder.
    van Winkel R; De Hert M; Van Eyck D; Hanssens L; Wampers M; Scheen A; Peuskens J
    Bipolar Disord; 2008 Mar; 10(2):342-8. PubMed ID: 18271914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic consequences of antipsychotic therapy: preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesity.
    Heal DJ; Gosden J; Jackson HC; Cheetham SC; Smith SL
    Handb Exp Pharmacol; 2012; (212):135-64. PubMed ID: 23129331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
    McIntyre RS; Jerrell JM
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity, diabetes and hypertension associated with antipsychotic use in remitted schizophrenia.
    Saddichha S; Vishnuvardhan G; Akhtar S
    Int J Risk Saf Med; 2011; 23(3):181-5. PubMed ID: 22020398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity and metabolic syndrome in a psychiatric rehabilitation service.
    Tirupati S; Chua LE
    Aust N Z J Psychiatry; 2007 Jul; 41(7):606-10. PubMed ID: 17558623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of monitoring and management guidelines for second-generation antipsychotics.
    Sernyak MJ
    J Clin Psychiatry; 2007; 68 Suppl 4():14-8. PubMed ID: 17539695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome evaluation of a structured educational wellness program in patients with severe mental illness.
    Lindenmayer JP; Khan A; Wance D; Maccabee N; Kaushik S; Kaushik S
    J Clin Psychiatry; 2009 Oct; 70(10):1385-96. PubMed ID: 19778494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study.
    de Simone G; Devereux RB; Chinali M; Best LG; Lee ET; Galloway JM; Resnick HE;
    Diabetes Care; 2007 Jul; 30(7):1851-6. PubMed ID: 17440172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.